FORM 7  
  
MONTHLY PROGRESS REPORT

Name of Listed Issuer: CANSORTIUM INC. (the “Issuer”).

Trading Symbol: TIUM

Number of Outstanding Listed Securities: 90,017,171 Common Shares and 21,386,448 Warrants as at November 30, 2019

Date: December 6, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**Response:** The Issuer has seen continued strong growth of its Florida business and shared progress on the implementation of key elements of its new growth plan to attract capital and strategic operating partners to drive sustainable, profitable growth. See the Issuer’s press release dated November 6th, 2019.

The Issuer has expanded its Florida retail dispensary footprint with the opening of its 17th medical marijuana dispensary in Florida. See the Issuer’s press release dated November 18, 2019.

The Issuer has been focusing on operations as well as exploring potential expansion opportunities and the divestiture of non-core assets.

1. Provide a general overview and discussion of the activities of management.

**Response:** Management has been actively involved in managing operations and continued expansion of the business. Management is continuing to evaluate ways to sell non-core assets and optimize operations and growth plans.

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Response:** There were no new products or services developed.

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Response:** There are no changes to the report.

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Response:** There are no changes to the report.

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Response:** There are no changes to the report.

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Response:** On November 14, 2019, the Company entered into a share purchase agreement with Brian Lagerwerf, Jennifer Weessies and 2638116 Ontario Inc. (their holding company) pursuant to which the Company agreed to sell 1931074 Ontario Inc. (the “Corporation”) for an undisclosed amount (the “Transaction”). Brian Lagerwerf and Jennifer Weessies were the former owners of the Corporation and the Company’s in-market partners in Canada. Closing of the Transaction is subject to obtaining approval from Health Canada as well as approval pursuant to the secured trust indenture dated May 23,2019. See the Issuer’s press release dated November 29, 2019.

As part of the Canada Transaction, the Buyer assumed the operational costs of 1931074 Ontario Inc., resulting in the reduction of the Issuer’s monthly employment costs of CAD $35,000 As part of the Canada Transaction, the Buyer assumed the operational costs of 1931074 Ontario Inc., resulting in the reduction of the Issuer’s monthly employment costs of CAD $35,000.

1. Describe the acquisition of new customers or loss of customers.

**Response:** The Issuer continues to acquire new customers as a result of expanding markets, increased production and dispensary and product expansion.

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Response:** There are no changes to the report.

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Response:**

* 15 employees were terminated.
* 7 new employees were hired.

1. Report on any labour disputes and resolutions of those disputes if applicable.

**Response:** N/A

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Response:** On November 6, 2019, the American Arbitration Association received a Demand for Arbitration filed by Woodmere Health Partners, LLC (“Woodmere”), a former member in Cansortium Health Partners, LLC (“CHP”), to determine its rights in approximately 4.8m common shares of the Issuer. Woodmere received certain rights to that stock, subject to vesting requirements, in exchange for converting its membership interests in CHP into units of Cansortium Holdings, LLC prior to the Issuer’s IPO. The common shares of the Issuer were subject to vesting requirements that were not satisfied, such as the receipt of a clinical registrant license in Pennsylvania. The Issuer is vigorously defending itself and does not believe that the outcome will have a material impact on the financial condition of the Issuer.

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Response:** There are no changes to the report.

1. Provide details of any securities issued and options or warrants granted.

**Response:** There are no changes to report.

1. Provide details of any loans to or by Related Persons.

**Response:** There are no changes to report.

1. Provide details of any changes in directors, officers or committee members.

**Response:** The Issuer announced that Marcos Pedreira, who had previously been chosen by the Board to become CFO of the Issuer in order for Henry Batievsky to focus efforts on production, has decided to remain Head of Finance. Mr. Batievsky will therefore continue to serve as the Issuer's CFO, as well as oversee production. See the Issuer’s press release dated November 29th, 2019.

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**Response:** There are no changes to report.

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 6, 2019 .

Todd Buchman   
Name of Director or Senior Officer

*[signed] Todd Buchman \_*   
Signature

Chief Legal Officer   
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***  Name of Issuer  Cansortium Inc. | For Month End  November 2019 | Date of Report  YY/MM/D  19/12/6 |
| Issuer Address  82 NE, 26th Street, Unit 110 | | |
| City/Province/Postal Code  Miami, FL 22137 | Issuer Fax No.  ( ) N/A | Issuer Telephone No.  (305) 900-6266 |
| Contact Name  Todd Buchman | Contact Position: Chief Legal Officer | Contact Telephone No.  305-441-9085 |
| Contact Email Address  [Todd.buchman@getfluent.com](mailto:Todd.buchman@getfluent.com) | Web Site Address  [www.cansortium.com](http://www.cansortium.com) | |